Ann: Letter to Shareholders from the Board of Ave, page-11

re: Ann: Letter to Shareholders from the Boar... Hi there Jevalent,

Its not difficult to understand I wouldn't have thought.... do what the EGM folk are suggesting and then if that doesn't work do what's happening now. That's hardly open ended. No going it alone with trials, no big cash drain. Simply got to the FDA and ask what they recommend (if anything) re getting ATC to market given the phase 3 results. Then, with that knowledge in hand, go to the obvious companies, and see what they say. At that point the news will be good or the news will be bad. If good, hooray. If bad, oh well, at least we tried. Where's the big risk there?

We can all take our best guess at what the FDA would say is needed re trials etc to get to market, and we can all have a guess at what that would cost and what the likely reward might be. Only the FDA knows though. Surely it makes sense to at least consult with them and then talk to companies with the firm knowledge of what the FDA think is needed. Why wouldn't that info be of use in the negotiations with the regional companies anyway? What exactly is the reason not to try that? And sorry...but saying "I reckon it won't work ..." is not enough. I agree the chances of it succeeding are slim, but I don't want them canning the program on guesswork. If there's a 1% chance of increasing the value of a deal from this, and it costs almost nothing to try, then give it a shot.